Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4630452 | 0.89 | CTSK (0.48) | CTSKBTKCA1CA2NFKB1 | |
| SCHEMBL7283644 | 0.74 | CTSK (0.67) | CTSKBTKCA1CA2CYP2C9 | |
| SCHEMBL6826856 | 0.72 | CTSK (0.76) | CTSKBTKCA1CA2CYP2C9 | |
| SCHEMBL1307244 | 0.72 | CTSK (0.76) | CTSKBTKCA1CA2CYP2C9 | |
| SCHEMBL6039889 | 0.71 | HRH3 (0.38) | CTSKEPHX1KMT2A | |
| SCHEMBL9078128 | 0.71 | HSD17B10 (0.48) | CTSKBTKCA1CA2NFKB1 | |
| SCHEMBL2025019 | 0.70 | BTK (0.50) | CTSKBTKCA1CA2NFKB1 | |
| SCHEMBL14941684 | 0.70 | CTSK (0.64) | CTSKBTKCA1CA2CYP2C9 | |
| Bicarbonate SCHEMBL187492 | 0.70 | BTK (0.62) | CTSKBTKCA1CA2NFKB1 | |
| SCHEMBL3702152 | 0.69 | BTK (0.61) | CTSKBTKCA1CA2NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710054-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2014-04-29 | — | — | US | disclosed |
| EP-2170906-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2013-04-03 | — | — | EP | disclosed |
| US-20130079330-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA, S.A. (BE) | 2013-03-28 | — | — | US | disclosed |
| US-8338592-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2012-12-25 | — | — | US | disclosed |
| US-8242116-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2012-08-14 | — | — | US | disclosed |
| EP-2035436-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-05-25 | — | — | EP | disclosed |
| US-20110003785-A1 | Fused Thiazole Derivatives As Kinase Inhibitors | UCB PHARMA, S.A. (BE) | 2011-01-06 | — | — | US | disclosed |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-06-03 | — | — | US | disclosed |
| EP-2170906-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009122148-A1 | FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009071888-A1 | PYRROLOTHIAZOLES AS PI3-KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071890-A1 | TRICYCLIC KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071895-A1 | FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| EP-2035436-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2009001089-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-12-31 | — | — | WO | disclosed |
| WO-2008001076-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003785-A1 | Fused Thiazole Derivatives As Kinase Inhibitors | PI4KA, PDPK1, MAP4K2 | CTSK 1058/4885BTK 36/4885CA1 4221/4885 |
| US-20130079330-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | PI4KA, PDPK1, MAP4K2 | CTSK 1058/4885BTK 36/4885CA1 4221/4885 |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | CTSK 1308/4885BTK 41/4885CA1 4251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.